Regulatory & Compounding Status (April 2026)
Triptorelin pamoate is an FDA-approved prescription medication (marketed as Trelstar, Triptodur, and Decapeptyl). This monograph documents analytical, chromatographic, and receptor pharmacology reference specifications strictly for in vitro and preclinical laboratory research.
Molecular Properties
| Parameter | Specification |
|---|---|
| Chemical Name | Triptorelin Acetate / [D-Trp6]-LHRH |
| Amino Acid Sequence | pGlu-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-Gly-NH2 |
| Molecular Formula | C64H82N18O13 (free base) |
| Molecular Weight | 1311.45 g/mol (1311.47 g/mol free base; 1431.55 g/mol acetate salt) |
| CAS Number | 57773-63-4 (free base); 140194-24-7 (acetate) |
| Chain Length | 10 amino acids |
| Structure Type | Linear decapeptide with N-terminal pyroglutamic acid, D-Trp6 substitution, and C-terminal amide |
Physical Properties
| Property | Value / Range |
|---|---|
| Appearance | White to off-white lyophilized powder |
| Solubility (Water) | Soluble (≥2 mg/mL in sterile water) |
| Solubility (Buffer) | Soluble in 0.9% NaCl, PBS, DMSO, and dilute acetic acid (≥1 mg/mL) |
| pH Range (1 mg/mL) | 5.0–6.5 (reconstituted in water) |
| Stability (Lyophilized) | Stable for 36 months at -20°C, protected from light and moisture |
| Stability (Reconstituted) | 14–21 days at 4°C; 3–6 months at -20°C (single-use aliquots) |
Analytical Specifications
| Test Parameter | Method | Acceptance Criteria |
|---|---|---|
| Purity | RP-HPLC (C18 column, 220 nm) | ≥98.0% |
| Molecular Identity | ESI-MS or MALDI-TOF MS | [M+H]+ = 1311.47 ± 0.5 Da |
| Peptide Content | Amino Acid Analysis / Nitrogen Content | ≥95% |
| Endotoxin Level | LAL Assay (USP <85>) | <1.0 EU/mg |
| Acetate Content | Ion Chromatography | 8–12% (acetate salt) |
| TFA Content | Ion Chromatography | ≤0.1% |
| Water Content | Karl Fischer Titration | ≤6% |
Storage Parameters
- Long-term Storage: -20°C or -80°C in sealed vials under inert gas (nitrogen or argon)
- Short-term Storage: 2–8°C for up to 1 month (lyophilized form)
- Reconstituted Solution: Store at 4°C for up to 2 weeks or aliquot and freeze at -20°C (avoid repeated freeze-thaw cycles)
- Protection: Shield from light exposure (contains two Trp residues sensitive to photo-oxidation) and moisture
- Container: Amber glass or low-binding polypropylene vials recommended
In Vitro & Preclinical Model Concentrations
| Application | Concentration / Protocol | Route / Media |
|---|---|---|
| In Vitro Pituitary Culture | 0.1–10 nM (0.13–13 ng/mL) | Direct addition to culture media |
| Rodent Models (Acute Flare) | 50–500 μg/kg body weight (single dose) | Subcutaneous (SC) or Intraperitoneal (IP) |
| Receptor Desensitization | 100–200 μg/kg daily for 7–28 days | Subcutaneous (SC) |
| Gonadal Suppression Models | 0.5–2 mg/kg (depot formulation, monthly) | Intramuscular (IM) |
Laboratory Solvent Preparation: Dissolve in sterile water, 0.9% NaCl, or bacteriostatic water at 1 mg/mL; dilute in sterile PBS or culture media for working solutions.
Key Research Studies
| Year | Study Focus | Key Findings |
|---|---|---|
| 1982 | Superagonist potency characterization | D-Trp6 substitution increased GnRHR binding affinity 50–100 fold vs. native GnRH; demonstrated EC50 of 0.01–0.05 nM for LH release from rat pituitary cells |
| 1995 | Pharmacokinetics and receptor dynamics | Single SC dose (100 μg/kg) produced initial LH surge at 4h followed by sustained suppression for 14–28 days; receptor downregulation detected by day 7 with >80% reduction in GnRHR density |
| 2004 | Depot formulation development | Biodegradable microsphere depot released triptorelin over 1–3 months; maintained therapeutic suppression with single injection; plasma levels 0.5–2 ng/mL sustained gonadal axis suppression |
| 2012 | Structure-activity and metabolic stability | D-amino acid at position 6 conferred peptidase resistance; plasma half-life extended to 3–5 hours vs. 2–4 minutes for native GnRH; metabolic stability increased 50–100 fold |
Mechanism of Action
- Receptor Binding: High-affinity superagonist at pituitary gonadotropin-releasing hormone receptors (GnRHR, Kd ~0.1–0.5 nM; 50–100x higher affinity than native GnRH).
- Initial Agonist Effect ("Flare"): First 2–7 days: supraphysiological GnRHR activation triggers an LH/FSH surge and transient increase in sex steroids.
- Receptor Downregulation: Continuous GnRHR stimulation induces receptor internalization and degradation, producing a 70–90% reduction in receptor density by day 14.
- Gonadal Suppression: Sustained receptor desensitization leads to loss of pulsatile LH/FSH secretion and a hypogonadal state.
- Half-Life: Plasma elimination half-life of 3–5 hours (SC) compared to 2–4 minutes for native gonadorelin; depot formulations provide sustained release over weeks to months.
Comparative Analysis: Triptorelin vs. Native GnRH
| Parameter | Native GnRH (Gonadorelin) | Triptorelin ([D-Trp6]-GnRH) |
|---|---|---|
| Position 6 Amino Acid | Gly (L-amino acid) | D-Trp (D-amino acid) |
| Receptor Affinity (Kd) | 1–5 nM | 0.1–0.5 nM (50–100x higher) |
| Half-Life (SC) | 2–4 minutes | 3–5 hours (75–150x longer) |
| Potency (LH release EC50) | 0.5–2 nM | 0.01–0.05 nM (50–200x more potent) |
| Primary Effect | Pulsatile stimulation | Biphasic: initial surge then suppression |
Quality Control Parameters
| Test Method | Acceptance Criteria |
|---|---|
| Appearance (visual) | White to off-white powder; no discoloration |
| Chiral Purity (D-Trp6) | D-isomer ≥99%; L-isomer <1% at position 6 |
| RP-HPLC (purity) | Main peak ≥98.0%; no single impurity >0.5% |
| ESI-MS (identity) | [M+H]+ = 1311.47 ± 0.5 Da confirmed |
| Biological Activity | ≥90% potency vs. reference standard in LH release assay |
Primary Scientific References
- Engel JB, Schally AV. Drug Insight: clinical use of agonists and antagonists of luteinizing-hormone-releasing hormone. Nat Clin Pract Endocrinol Metab. 2007;3(2):157-167. PubMed: 17237843
- National Center for Biotechnology Information. PubChem Compound Summary for Triptorelin. PubChem: Triptorelin
- Limonta P, Marelli MM, Mai S, Motta M, Martini L, Moretti RM. GnRH receptors in cancer: from cell biology to novel targeted therapeutic strategies. Endocr Rev. 2012;33(5):784-811. PMC3461332
